Dec 10, 2009
Hyperion Therapeutics Enrolls First Patient In Phase II Hepatic Encephalopathy Trial
Hyperion Therapeutics, Inc. announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open label safety component followed by a randomized, double-blind, placebo-controlled study that will enroll approximately 140 patients with episodic hepatic encephalopathy in the US and Eastern Europe.